Prolor Biotech Inc. (AMEX: PBTH) will present data from its longer-acting human growth hormone (hGH-CTP) program in a presentation at the 5th International Congress Of The Growth Hormone Research Society (GRS) and IGF Society on October 4th.
Prolor is developing hGH-CTP to provide growth hormone-deficient adults and children with therapy that requires only once-weekly or twice-monthly injections, as opposed to the multiple injections per week required by current growth hormone regimens.
Prolor develop improved versions of existing drugs, which, for example, can retain the same effectiveness as the original medication but with fewer dosages.
hGH-CTP is currently in a Phase II clinical trial following a successful Phase I trial that showed that hGH-CTP could potentially be effective when injected just twice per month. The trial is being conducted at up to 14 sites in six countries. PROLOR expects to complete the Phase II trial in 2011.
Prolor CEO Dr. Abraham Havron said, "We are pleased to have the opportunity to present our hGH-CTP program to the leading growth hormone academic and industry researchers from around the globe who will be participating in this important meeting. We are especially honored to be one of only three companies selected to participate in the scientific program."
The 5th International Congress will be held at the Sheraton New York Hotel in New York City from October 3-6.
The Growth Hormone Research Society (GRS) was founded in 1992 to provide a forum for the study and exchange of ideas on all aspects of growth hormone physiology.
Prolor shares closed at $6.42 on Friday, giving a market cap of $341.6 million.
Published by Globes [online], Israel business news - www.globes-online.com - on September 27, 2010
© Copyright of Globes Publisher Itonut (1983) Ltd. 2010